Prophase Labs Inc's fundamentals are relatively weak, and its growth potential is good.Its valuation is considered fairly valued, ranking 70/78 in the Healthcare Providers & Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at 16.00.In the medium term, the stock price is expected to trend up.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Prophase Labs Inc's Score
Industry at a Glance
Industry Ranking
70 / 78
Overall Ranking
459 / 4562
Industry
Healthcare Providers & Services
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
16.000
Target Price
+5111.73%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Prophase Labs Inc Highlights
StrengthsRisks
ProPhase Labs, Inc. is a biotech, genomics, and consumer products company. The Company is engaged in providing whole genome sequencing solutions, diagnostic development, such as its potentially life-saving test for the early detection of esophageal cancer and a direct-to-consumer marketing platform for OTC dietary supplements. It develops, manufactures, and commercializes health and wellness solutions. Its Diagnostic services segment provides diagnostic information services to a range of customers in the United States, including health plans, third-party payers and government organizations. Its Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and provides personal genomics products and services. The Company also develops and markets dietary supplements under the TK Supplement brand, which includes Legendz XL and Triple Edge XL.
Growing
The company is in a growing phase, with the latest annual income totaling USD 6.77M.
Overvalued
The company’s latest PE is -0.03, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 3.04M shares, decreasing 45.19% quarter-over-quarter.
ProPhase Labs, Inc. is a biotech, genomics, and consumer products company. The Company is engaged in providing whole genome sequencing solutions, diagnostic development, such as its potentially life-saving test for the early detection of esophageal cancer and a direct-to-consumer marketing platform for OTC dietary supplements. It develops, manufactures, and commercializes health and wellness solutions. Its Diagnostic services segment provides diagnostic information services to a range of customers in the United States, including health plans, third-party payers and government organizations. Its Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and provides personal genomics products and services. The Company also develops and markets dietary supplements under the TK Supplement brand, which includes Legendz XL and Triple Edge XL.
Ticker SymbolPRPH
CompanyProphase Labs Inc
CEOKarkus (Ted William)
Websitehttps://www.prophaselabs.com/
FAQs
What is the current price of Prophase Labs Inc (PRPH)?
The current price of Prophase Labs Inc (PRPH) is 0.615.
What is the symbol of Prophase Labs Inc?
The ticker symbol of Prophase Labs Inc is PRPH.
What is the 52-week high of Prophase Labs Inc?
The 52-week high of Prophase Labs Inc is 9.349.
What is the 52-week low of Prophase Labs Inc?
The 52-week low of Prophase Labs Inc is 0.639.
What is the market capitalization of Prophase Labs Inc?
The market capitalization of Prophase Labs Inc is 2.55M.
What is the net income of Prophase Labs Inc?
The net income of Prophase Labs Inc is -53.36M.
Is Prophase Labs Inc (PRPH) currently rated as Buy, Hold, or Sell?
According to analysts, Prophase Labs Inc (PRPH) has an overall rating of --, with a price target of 16.000.
What is the Earnings Per Share (EPS TTM) of Prophase Labs Inc (PRPH)?
The Earnings Per Share (EPS TTM) of Prophase Labs Inc (PRPH) is -17.761.